Top Abstract Purchase Related
Home
>
Node
>
Subnode

Advances in prostate-specific membrane antigen targeted therapies for prostate cancer

Wang, W.; Mo, Z.-N.

Zhonghua Nan Ke Xue 16(6): 547-551

2010

ISSN/ISBN: 1009-3591
PMID: 20608362
Document Number: 646722
Prostate-specific membrane antigen (PSMA) is a type II integral membrane glycoprotein, specifically expressed in prostatic epithelial cells and strongly upregulated in prostate cancer. PSMA is also present in the neovasculature of other solid tumors. These findings have spurred the development of PSMA-targeted therapies for prostate cancer, including immunotherapy, radioimmunotherapy, chemotherapy and gene therapy, and initiated the clinical trials of the first-generation products. However, general clinical application of these therapies still requires extensive clinical studies to test their clinical safety, stability and efficacy.

Document emailed within 1 workday
Secure & encrypted payments

Romppanen, J.; Haapalainen, T.; Punnonen, K.; Penttilä, I. 2002: Serum sialic acid and prostate-specific antigen in differential diagnosis of benign prostate hyperplasia and prostate cancer Anticancer Research 22(1a): 415-420
Stenman, U.H.; Leinonen, J.; Alfthan, H.; Rannikko, S.; Tuhkanen, K.; Alfthan, O. 1991: A complex between prostate-specific antigen and alpha 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer Cancer Research 51(1): 222-226
Bostwick, D.G. 1994: Prostate-specific antigen. Current role in diagnostic pathology of prostate cancer American Journal of Clinical Pathology 102(4 Suppl 1): S31-S37
Fornara, P.; Sturm, W.; Fabricius, P.G.; Schmiedt, E. 1987: Clinical relevance of radioimmunologic determination of prostate specific antigen in prostate cancer Der Urologe. Ausg. a 26(3): 158-161
Schäfer, U.; Micke, O.; Hampel, G.; Brandt, B.; Bovenschulte, A.; Semjonow, A.; Willich, N. 1997: The use of prostate-specific antigen (PSA) for the monitoring of radiation therapy in prostate cancer Anticancer Research 17(4b): 2983-2986
Kelly, W.K.; Slovin, S.; Scher, H.I. 1996: Clinical use of posttherapy prostate-specific antigen changes in advanced prostate cancer Seminars in Oncology 23(6 Suppl 14: 8-14
Maeda, H.; Arai, Y.; Ishitoya, S.; Okubo, K.; Aoki, Y.; Okada, T.; Maekawa, S. 1998: Free-to-total prostate specific antigen ratio in clinical staging of prostate cancer Hinyokika Kiyo. Acta Urologica Japonica 44(5): 307-311
Horiguchi, A.; Hatakeyama, N.; Ikeuchi, K. 1999: Dynamics of prostate-specific antigen as prognostic factors in endocrine treatment for prostate cancer Hinyokika Kiyo. Acta Urologica Japonica 45(1): 31-35
Amayo, A.; Obara, W. 2004: Serum prostate specific antigen levels in men with benign prostatic hyperplasia and cancer of prostate East African Medical Journal 81(1): 22-26
Serdar, M.A.; Oguz, O.; Olgun, A.; Seçkin, B.; Ilgan, S.; Hasimi, A.; Salih, M.; Peker, F.; Kutluay, T. 2002: Diagnostic approach to prostate cancer using total prostate specific antigen-based parameters together Annals of Clinical and Laboratory Science 32(1): 22-30
Hardeman, S.W.; Wake, R.W.; Soloway, M.S. 1989: Two new techniques for evaluating prostate cancer. The role of prostate-specific antigen and transrectal ultrasound Postgraduate Medicine 86(2): 197-8 201 204 Passim
O'Dell, K.J.; Volk, R.J.; Cass, A.R.; Spann, S.J. 1999: Screening for prostate cancer with the prostate-specific antigen test: are patients making informed decisions? Journal of Family Practice 48(9): 682-688
Miyamoto, S.; Jimbo, H.; Totsuka, Y.; Mashimo, T.; Umeyama, T.; Uehara, H.; Shinozaki, T. 1995: Change in serum prostate specific antigen values in men who had no evidence of prostate cancer on initial biopsy Hinyokika Kiyo. Acta Urologica Japonica 41(10): 767-770
De la Taille, A.; Houlgatte, A.; Houdelette, P.; Berlizot, P.; Ramirez, J.; Ricordel, I. 1997: Value of free/total prostate specific antigen in the early diagnosis of prostate cancer (study of 105 patients) Progres en Urologie: Journal de l'Association Francaise d'Urologie et de la Societe Francaise d'Urologie 7(2): 240-245
Parkes, C.; Wald, N.J.; Murphy, P.; George, L.; Watt, H.C.; Kirby, R.; Knekt, P.; Helzlsouer, K.J.; Tuomilehto, J. 1995: Prospective observational study to assess value of prostate specific antigen as screening test for prostate cancer BMJ 311(7016): 1340-1343
Topuzov, M.E. 2007: Role of density of prostate-specific antigen transitory zone in early diagnosis of prostate cancer Voprosy Onkologii 53(3): 295-297
Galić, J.; Karner, I.; Cenan, L.; Tucak, A.; Hegedus, I.; Pasini, J.; Bilandzija-Peranović, M.; Mihaljević, S. 2003: Comparison of digital rectal examination and prostate specific antigen in early detection of prostate cancer Collegium Antropologicum 27(Suppl 1): 61-66
Leewansangtong, S.; Soontrapa, S.; Tantiwong, A. 1999: Is prostate-specific antigen still the best tumor marker for prostate cancer? Journal of the Medical Association of Thailand 82(10): 1034-1040
Jung, P.; Wolff, J.M.; Mattelaer, P.; Jakse, G. 1996: Prostate specific antigen in the diagnosis and staging of prostate cancer Acta Urologica Belgica 64(3): 1-6
Su, H.-W.; Li, Y.; Xu, P. 2003: Diagnostic value of complexed prostate-specific antigen for prostate cancer Zhonghua Nan Ke Xue 9(6): 431-433